1. Side effects of drug-antibody conjugates enfortumab-vedotin and sacituzumab-govitecan in targeted therapy in cancer
   Moritz J. Reike et al, 2024, Cancer Epidemiology CrossRef
2. Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors
   Fanfan Li et al, 2022, Frontiers in Immunology CrossRef
3. Precision Medicine in Urothelial Carcinoma: Current Markers to Guide Treatment and Promising Future Directions
   Eric J. Miller et al, 2023, Current Treatment Options in Oncology CrossRef
4. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer
   Yue Wu et al, 2024, Journal of Nanobiotechnology CrossRef
5. Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis
   Kavita A. Iyer et al, 2024, Journal of Medicinal Chemistry CrossRef
6. Gene expression of Nectin‐4 and its clinical significance in dogs with primary lung adenocarcinoma
   Kei Tamura et al, 2022, Veterinary Medicine and Science CrossRef
7. An Analysis of Nectin-4 (PVRL4) in Penile Squamous Cell Carcinoma
   G.Daniel Grass et al, 2023, European Urology Open Science CrossRef
8. Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker
   Marcel Mayer et al, 2023, Clinical & Experimental Metastasis CrossRef
9. Like Father, Like Daughter – Ectodermal Dysplasia-Syndactyly Syndrome: A Case Report
   Gopika JITH et al, 2024, The Journal of Hand Surgery (Asian-Pacific Volume) CrossRef
10. Antibody drug conjugate: the “biological missile” for targeted cancer therapy
    Zhiwen Fu et al, 2022, Signal Transduction and Targeted Therapy CrossRef
11. Antibody drug conjugates: The dos and don'ts in clinical development
    Anthony W. Tolcher, 2022, Pharmacology & Therapeutics CrossRef
12. Antibody–Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading?
    Pierluigi De Santis et al, 2023, Journal of Clinical Medicine CrossRef
13. Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings
    Dylan Haynes et al, 2023, Human Pathology CrossRef
14. Arising Novel Agents in Lung Cancer: Are Bispecifics and ADCs the New Paradigm?
    Amanda Reyes et al, 2023, Cancers CrossRef
15. BMSC derived EVs inhibit colorectal Cancer progression by transporting MAGI2-AS3 or something similar
    Tianyi Ma et al, 2024, Cellular Signalling CrossRef
16. Pembrolizumab plus enfortumab vedotin in urothelial cancer
    Matteo Santoni et al, 2024, Nature Reviews Urology CrossRef
17. Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
    Thomas Grinda et al, 2023, Current Treatment Options in Oncology CrossRef
18. Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
    Catherine C. Fahey et al, 2023, International Journal of Molecular Sciences CrossRef
19. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
    Florence Boissière-Michot et al, 2022, Frontiers in Immunology CrossRef
20. Gegen Nectin-4 gerichtete Antikörper-Wirkstoff-Konjugate als neue Behandlungsoption für Patienten mit metastasiertem Urothelkarzinom
    Niklas Klümper et al, 2023, Die Urologie CrossRef
21. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence
    Mohammad Javad Khosravanian et al, 2024, Life Sciences CrossRef
22. Antibody–Drug Conjugates in the Treatment of Urothelial Cancer
    Avani M. Singh et al, 2023, BioDrugs CrossRef
23. Nectins and Nectin-like Molecules in Colorectal Cancer: Role in Diagnostics, Prognostic Values, and Emerging Treatment Options: A Literature Review
    Jakub Kobecki et al, 2022, Diagnostics CrossRef
24. LncRNA NORAD regulates the mechanism of the miR-532-3p/Nectin-4 axis in pancreatic cancer cell proliferation and angiogenesis
    Kaiqiong Wang et al, 2023, Toxicology Research CrossRef